Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 20/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3579697 | 0.92 | PDE5A (0.76) | PDE5A | |
| SCHEMBL3586544 | 0.91 | PDE5A (0.80) | PDE5A | |
| SCHEMBL3586537 | 0.91 | PDE5A (0.80) | PDE5A | |
| SCHEMBL3576653 | 0.91 | PDE5A (0.80) | PDE5A | |
| SCHEMBL4559196 | 0.90 | PDE5A (0.80) | PDE5A | |
| SCHEMBL3575355 | 0.88 | PDE5A (0.79) | PDE5A | |
| SCHEMBL3575352 | 0.88 | PDE5A (0.79) | PDE5A | |
| SCHEMBL3576122 | 0.88 | PDE5A (0.79) | PDE5A | |
| SCHEMBL6443311 | 0.87 | PDE5A (0.80) | PDE5A | |
| SCHEMBL13500475 | 0.87 | PDE5A (0.85) | PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1536782-B1 | SYNERGISTIC COMBINATION OF AN ALPHA-2-DELTA LIGAND AND A PDEV INHIBITOR FOR USE IN THE TREATMENT OF PAIN | PFIZER LTD (GB) | 2007-04-18 | — | — | EP | claimed |
| US-20110212972-A1 | Compositions and Methods for Treating Female Sexual Dysfunction | PFIZER INC | 2011-09-01 | — | — | US | disclosed |
| US-20090264413-A1 | Compositions and Methods for Treating Female Sexual Dysfunction | PFIZER INC. | 2009-10-22 | — | — | US | disclosed |
| EP-1440709-B1 | Combinations comprising cGMP PDE5 inhibitors. | PFIZER LTD (GB) | 2007-12-05 | — | — | EP | disclosed |
| EP-1149579-B1 | Use of an estrogen agonist/antagonist for treating female sexual dysfunction | PFIZER PROD INC (US) | 2006-12-06 | — | — | EP | disclosed |
| US-7067660-B2 | such as 1-(4-ethoxy-3-formylphenylsulfonyl)-4-methylpiperazine; for use as anti-impotence agent | PFIZER INC. (US) | 2006-06-27 | — | — | US | disclosed |
| EP-1653966-A1 | TREATMENT OF SEXUAL DYSFUNCTION | Pfizer Limited (GB) | 2006-05-10 | — | — | EP | disclosed |
| US-7005520-B2 | Process for the preparation of pyrazolopyrimidinones | PFIZER INC. (US) | 2006-02-28 | — | — | US | disclosed |
| US-20050065158-A1 | Treatment of sexual dysfunction | PFIZER INC. | 2005-03-24 | — | — | US | disclosed |
| WO-2005007166-A1 | TREATMENT OF SEXUAL DYSFUNCTION | PFIZER LIMITED (GB) | 2005-01-27 | — | — | WO | disclosed |
| US-20030083228-A1 | Treatments for female sexual dysfunction and methods for identifying compounds useful for treating female sexual dysfunction | CARPINO PHILIP A (US) | 2003-05-01 | — | — | US | disclosed |
| EP-1285658-A2 | Treatments for female sexual dysfunction | Pfizer Productors Inc. (US) | 2003-02-26 | — | — | EP | disclosed |
| US-6512002-B2 | Treating timidity and enhancing libido in postmenopausal women, or treating male sexual dysfunction by administering to a patient in need thereof an effective amount of an estrogen agonist/antagonist | PFIZER INC. | 2003-01-28 | — | — | US | disclosed |
| US-20020013464-A1 | Novel process for the preparation of pyrazolopyrimidinones | PFIZER INC. | 2002-01-31 | — | — | US | disclosed |
| US-20020013465-A1 | Novel process for the preparation of pyrazolopyrimidinones | PFIZER INC. | 2002-01-31 | — | — | US | disclosed |
| US-20020013327-A1 | Compositions and methods for treating female sexual dysfunction | LEE ANDREW G (US) | 2002-01-31 | — | — | US | disclosed |
| US-20010044434-A1 | Compositions and methods of treatment for conditions responsive to testosterone elevation | LEE ANDREW G (US) | 2001-11-22 | — | — | US | disclosed |
| EP-1149579-A2 | Use of an estrogen agonist/antagonist for treating female sexual dysfunction | Pfizer Products Inc. (US) | 2001-10-31 | — | — | EP | disclosed |
| EP-1129706-A2 | Use of cGMP PDE5 inhibitors for the treatment of neuropathy | Pfizer Limited (GB) | 2001-09-05 | — | — | EP | disclosed |
| EP-1125582-A2 | Use of estrogen agonists / antagonists for the treatment of sexual dysfunction | Pfizer Products Inc. (US) | 2001-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013465-A1 | Novel process for the preparation of pyrazolopyrimidinones | SDHA, NDUFS3, NDUFS2 | PDE5A 1679/4885 |
| US-20020013464-A1 | Novel process for the preparation of pyrazolopyrimidinones | CYP4F3, CYP3A4, NDUFS3 | PDE5A 895/4885 |
| US-20030083228-A1 | Treatments for female sexual dysfunction and methods for identifying compounds useful for treating female sexual dysfunction | MC1R, MCHR2, MC3R | PDE5A 208/4885 |
| US-20010044434-A1 | Compositions and methods of treatment for conditions responsive to testosterone elevation | PDE3B, PDE3A, SHBG | PDE5A 4/4885 |
| US-20090264413-A1 | Compositions and Methods for Treating Female Sexual Dysfunction | PDE3A, PDE3B, PDE2A | PDE5A 4/4885 |
| US-20020013327-A1 | Compositions and methods for treating female sexual dysfunction | PDE3A, PDE3B, PDE2A | PDE5A 4/4885 |
| US-20110212972-A1 | Compositions and Methods for Treating Female Sexual Dysfunction | PDE3A, PDE3B, PDE2A | PDE5A 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.